Ligand Pharmaceuticals Inc.  

(Public, NASDAQ:LGND)   Watch this stock  
Find more results for LGND
104.48
+0.85 (0.82%)
Dec 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 103.28 - 107.56
52 week 82.06 - 139.79
Open 104.47
Vol / Avg. 278,249.00/362,061.00
Mkt cap 2.22B
P/E     -
Div/yield     -
EPS -0.94
Shares 20.90M
Beta 1.37
Inst. own 119%
Feb 8, 2017
Q4 2016 Ligand Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 9, 2016
Ligand Pharmaceuticals Inc at Stephens Fall Investor Conference - Webcast
Nov 3, 2016
Q3 2016 Ligand Pharmaceuticals Inc Earnings Call
Nov 3, 2016
Q3 2016 Ligand Pharmaceuticals Inc Earnings Release
Sep 13, 2016
Ligand Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference - Webcast
Sep 12, 2016
Ligand Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 4.86% 316.27%
Operating margin 25.28% 77.20%
EBITD margin - 43.07%
Return on average assets 0.71% 59.77%
Return on average equity 1.26% 174.37%
Employees 21 -
CDP Score - -

Address

3911 Sorrento Valley Blvd Ste 110
SAN DIEGO, CA 92121-1402
United States - Map
+1-858-5507500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.

Officers and directors

John W. Kozarich Ph.D. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Matthew W. Foehr President, Chief Operating Officer
Age: 43
Bio & Compensation  - Reuters
John L. Higgins Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Matthew E. Korenberg Chief Financial Officer, Principal Accounting Officer, Vice President - Finance
Age: 41
Bio & Compensation  - Reuters
Charles S. Berkman J.D. Vice President, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Jason M. Aryeh Independent Director
Age: 47
Bio & Compensation  - Reuters
Todd C. Davis Independent Director
Age: 55
Bio & Compensation  - Reuters
John L. LaMattina Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Sunil Patel Independent Director
Age: 44
Bio & Compensation  - Reuters
Stephen L. Sabba M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters